Pharmacokinetics of and Rate of HIV-1 RNA Decline in ARV-naive HIV-1 Infected Patients Treated With Low- or Standard-dose Saquinavir HGC (Invirase) and Lopinavir/Ritonavir (Kaletra).

Trial Profile

Pharmacokinetics of and Rate of HIV-1 RNA Decline in ARV-naive HIV-1 Infected Patients Treated With Low- or Standard-dose Saquinavir HGC (Invirase) and Lopinavir/Ritonavir (Kaletra).

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Jun 2010

At a glance

  • Drugs Lopinavir/ritonavir; Saquinavir
  • Indications HIV-1 infections
  • Focus Pharmacokinetics; Therapeutic Use
  • Most Recent Events

    • 05 Dec 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top